Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3002
IPSCIO Record ID: 2806
IPSCIO Record ID: 7550
IPSCIO Record ID: 26064
Sublicenses – In the event that Licensee sublicenses any of its rights hereunder to a Sublicense, such sublicense shall include terms and conditions consistent with the terms and conditions of the license granted under this Agreement Sublicenses, if any, granted hereunder, will be to Third Parties in an arm's length transaction under written agreements, copies of which will be provided to Licensor.
The Company has evaluated the effects of removal of various mature cells by immvno selection and the depleted cells failed to expand. More recently we have evaluated the removal of red blood cells and have positive data for optimal removal of red cells and preliminary evidence that the red cell depleted products may expand up to 500 fold. This approach has a number of advantages including the passive removal of inhibitory cells which has minimal effect on total CD34+ cells. Future studies are required to generate data on the expansion potential of the depleted CB products, and this work will include proof of principle expo performed with frozen CB products to mimic the clinical setting.
The red cell depletion results in recovery of approx. 50 million white cells which would only be a cell dose 0.1 x 107 TNCI & With an expansion of only 100 fold this would result in a cell dose of 10.0 x 10' ThC/kg. Therefore an expansion of 500 fold would be sufficient for all adult patients to achieve a cell dose in the range of 10.0 x 107 TNC/kg, therefore making CB transplantation available to potential patients. In comparison, CD34 selection for expansion results in approx. 5 million cells post selection and would require an expansion of 1,000 fold or more to achieve similar cell doses. No studies have reported these levels of expansion consistently.
IPSCIO Record ID: 7221
The Licensee was not required to pay an upfront fees license fee.
IPSCIO Record ID: 3040
There are no incremental License fees associated with the expanded Licensed territory.
The Company recognizes revenue from processing fees upon completion of processing and storage fees ratably over the contractual storage period, as well as, other income from royalties paid by licensees related to long term storage contracts which the Company has under license agreements. Contracted storage periods can range from one to twenty-one years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee and the twenty-one year storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement.
IPSCIO Record ID: 168
Company granted an exclusive license to use its â€œACTCellerateâ€ embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.